Soluble suppression of tumorigenicity-2 in pregnancy with a small-for-gestational-age fetus and with preeclampsia

References

• Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol. 2004;190(6):1541–1547; discussion 47–50.
   PubMed Web of Science ®Google Scholar
• Torry DS, Wang HS, Wang TH, et al. Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol. 1998;179(6 Pt 1):1539–1544.
   PubMed Web of Science ®Google Scholar
• Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350(7):672–683.
   PubMed Web of Science ®Google Scholar
• Thadhani R, Mutter WP, Wolf M, et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab. 2004;89(2):770–775.
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Kim YM, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med. 2005;17(1):3–18.
   PubMed Web of Science ®Google Scholar
• Bujold E, Romero R, Chaiworapongsa T, et al. Evidence supporting that the excess of the sVEGFR-1 concentration in maternal plasma in preeclampsia has a uterine origin. J Matern Fetal Neonatal Med. 2005;18(1):9–16.
   PubMed Web of Science ®Google Scholar
• Crispi F, Domínguez C, Llurba E, et al. Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am J Obstet Gynecol. 2006;195(1):201–207.
   PubMed Web of Science ®Google Scholar
• Espinoza J, Romero R, Nien JK, et al. A role of the anti-angiogenic factor sVEGFR-1 in the 'mirror syndrome’ (Ballantyne’s syndrome). J Matern Fetal Neonatal Med. 2006;19(10):607–613.
   PubMed Web of Science ®Google Scholar
• Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355(10):992–1005.
   PubMed Web of Science ®Google Scholar
• Levine RJ, Qian C, Maynard SE, et al. Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. Am J Obstet Gynecol. 2006;194(4):1034–1041.
   PubMed Web of Science ®Google Scholar
• Robinson CJ, Johnson DD, Chang EY, et al. Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol. 2006;195(1):255–259.
   PubMed Web of Science ®Google Scholar
• Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12(6):642–649.
   PubMed Web of Science ®Google Scholar
• Gotsch F, Romero R, Friel L, et al. CXCL10/IP-10: a missing link between inflammation and anti-angiogenesis in preeclampsia? J Matern Fetal Neonatal Med. 2007;20(11):777–792.
   PubMed Web of Science ®Google Scholar
• Lindheimer MD, Romero R. Emerging roles of antiangiogenic and angiogenic proteins in pathogenesis and prediction of preeclampsia. Hypertension. 2007;50(1):35–36.
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Espinoza J, Gotsch F, et al. The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. J Matern Fetal Neonatal Med. 2008;21(1):25–40.
   PubMed Web of Science ®Google Scholar
• Erez O, Romero R, Espinoza J, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med. 2008;21(5):279–287.
   PubMed Web of Science ®Google Scholar
• Gotsch F, Romero R, Kusanovic JP, et al. Preeclampsia and small-for-gestational age are associated with decreased concentrations of a factor involved in angiogenesis: soluble Tie-2. J Matern Fetal Neonatal Med. 2008;21(6):389–402.
   PubMed Web of Science ®Google Scholar
• Maynard SE, Min J-Y, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649–658.
   PubMed Web of Science ®Google Scholar
• Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med. 2008;21(1):9–23.
   PubMed Web of Science ®Google Scholar
• Brosens I, Pijnenborg R, Vercruysse L, et al. The "Great Obstetrical Syndromes" are associated with disorders of deep placentation. Am J Obstet Gynecol. 2011;204(3):193–201.
   PubMed Web of Science ®Google Scholar
• Dekker GA, Sibai BM. Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol. 1998;179(5):1359–1375.
   PubMed Web of Science ®Google Scholar
• Papageorghiou AT, Yu CK, Bindra R, et al. Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation. Ultrasound Obstet Gynecol. 2001;18(5):441–449.
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Gervasi M-T, Refuerzo J, et al. Maternal lymphocyte subpopulations (CD45RA + and CD45RO+) in preeclampsia. Am J Obstet Gynecol. 2002;187(4):889–893.
   PubMed Web of Science ®Google Scholar
• Erez O, Romero R, Kim S-S, et al. Over-expression of the thrombin receptor (PAR-1) in the placenta in preeclampsia: a mechanism for the intersection of coagulation and inflammation. J Matern Fetal Neonatal Med. 2008;21(6):345–355.
   PubMed Web of Science ®Google Scholar
• Gervasi MT, Chaiworapongsa T, Pacora P, et al. Phenotypic and metabolic characteristics of monocytes and granulocytes in preeclampsia. Am J Obstet Gynecol. 2001;185(4):792–797.
   PubMed Web of Science ®Google Scholar
• Girardi G, Yarilin D, Thurman JM, et al. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med. 2006;203(9):2165–2175.
   PubMed Web of Science ®Google Scholar
• Kusanovic JP, Romero R, Hassan SS, et al. Maternal serum soluble CD30 is increased in normal pregnancy, but decreased in preeclampsia and small for gestational age pregnancies. J Matern Fetal Neonatal Med. 2007;20(12):867–878.
   PubMed Web of Science ®Google Scholar
• Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol. 1999;180(2 Pt 1):499–506.
   PubMed Web of Science ®Google Scholar
• Sabatier F, Bretelle F, D'ercole C, et al. Neutrophil activation in preeclampsia and isolated intrauterine growth restriction. Am J Obstet Gynecol. 2000;183(6):1558–1563.
   PubMed Web of Science ®Google Scholar
• Sacks GP, Studena K, Sargent K, et al. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am J Obstet Gynecol. 1998;179(1):80–86.
   PubMed Web of Science ®Google Scholar
• Schiff E, Friedman SA, Baumann P, et al. Tumor necrosis factor-alpha in pregnancies associated with preeclampsia or small-for-gestational-age newborns. Am J Obstet Gynecol. 1994;170(5 Pt 1):1224–1229.
   PubMed Web of Science ®Google Scholar
• Than NG, Erez O, Wildman DE, et al. Severe preeclampsia is characterized by increased placental expression of galectin-1. J Matern Fetal Neonatal Med. 2008;21(7):429–442.
   PubMed Web of Science ®Google Scholar
• Than NG, Romero R, Erez O, et al. A role for mannose-binding lectin, a component of the innate immune system in pre-eclampsia. Am J Reprod Immunol. 2008;60(4):333–345.
   PubMed Web of Science ®Google Scholar
• Bartha JL, Romero-Carmona R, Comino-Delgado R. Inflammatory cytokines in intrauterine growth retardation. Acta Obstet Gynecol Scand. 2003;82(12):1099–1102.
   PubMed Web of Science ®Google Scholar
• Clark BA, Halvorson L, Sachs B, et al. Plasma endothelin levels in preeclampsia: elevation and correlation with uric acid levels and renal impairment. Am J Obstet Gynecol. 1992;166(3):962–968.
   PubMed Web of Science ®Google Scholar
• Friedman SA, De Groot CJ, Taylor RN, et al. Plasma cellular fibronectin as a measure of endothelial involvement in preeclampsia and intrauterine growth retardation. Am J Obstet Gynecol. 1994;170(3):838–841.
   PubMed Web of Science ®Google Scholar
• Higgins JR, Papayianni A, Brady HR, et al. Circulating vascular cell adhesion molecule-1 in pre-eclampsia, gestational hypertension, and normal pregnancy: evidence of selective dysregulation of vascular cell adhesion molecule-1 homeostasis in pre-eclampsia. Am J Obstet Gynecol. 1998;179(2):464–469.
   PubMed Web of Science ®Google Scholar
• Kraayenbrink AA, Dekker GA, van Kamp GJ, et al. Endothelial vasoactive mediators in preeclampsia. Am J Obstet Gynecol. 1993;169(1):160–165.
   PubMed Web of Science ®Google Scholar
• Ness RB, Sibai BM. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gynecol. 2006;195(1):40–49.
   PubMed Web of Science ®Google Scholar
• Schiff E, Ben-Baruch G, Peleg E, et al. Immunoreactive circulating endothelin-1 in normal and hypertensive pregnancies. Am J Obstet Gynecol. 1992;166(2):624–628.
   PubMed Web of Science ®Google Scholar
• Villar J, Carroli G, Wojdyla D, et al. Preeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions? Am J Obstet Gynecol. 2006;194(4):921–931.
   PubMed Web of Science ®Google Scholar
• Grisaru-Granovsky S, Halevy T, Eidelman A, et al. Hypertensive disorders of pregnancy and the small for gestational age neonate: not a simple relationship. Am J Obstet Gynecol. 2007;196(4):335.e1–335.e5.
   PubMed Web of Science ®Google Scholar
• Mitani M, Matsuda Y, Makino Y, et al. Clinical features of fetal growth restriction complicated later by preeclampsia. J Obstet Gynaecol Res. 2009;35(5):882–887.
   PubMed Web of Science ®Google Scholar
• McCowan LM, North RA, Harding JE. Abnormal uterine artery Doppler in small-for-gestational-age pregnancies is associated with later hypertension. Aust N Z J Obstet Gynaecol. 2001;41(1):56–60.
   PubMed Web of Science ®Google Scholar
• Jung E, Romero R, Yeo L, et al. The etiology of preeclampsia. Am J Obstet Gynecol. 2022;226(2S):S844–S866.
   PubMedGoogle Scholar
• Erez O, Romero R, Jung E, et al. Preeclampsia and eclampsia: the conceptual evolution of a syndrome. Am J Obstet Gynecol. 2022;226(2S):S786–S803.
   PubMedGoogle Scholar
• Peine M, Marek RM, Löhning M. IL-33 in T cell differentiation, function, and immune homeostasis. Trends Immunol. 2016;37(5):321–333.
   PubMed Web of Science ®Google Scholar
• Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett. 1989;258(2):301–304.
   PubMed Web of Science ®Google Scholar
• Palmer G, Gabay C. Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol. 2011;7(6):321–329.
   PubMed Web of Science ®Google Scholar
• Alves-Filho JC, Sônego F, Souto FO, et al. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat Med. 2010;16(6):708–712.
   PubMed Web of Science ®Google Scholar
• Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479–490.
   PubMed Web of Science ®Google Scholar
• Zeyda M, Wernly B, Demyanets S, et al. Severe obesity increases adipose tissue expression of interleukin-33 and its receptor ST2, both predominantly detectable in endothelial cells of human adipose tissue. Int J Obes. 2013;37(5):658–665.
   Web of Science ®Google Scholar
• Demyanets S, Kaun C, Pentz R, et al. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J Mol Cell Cardiol. 2013;60:16–26.
   PubMed Web of Science ®Google Scholar
• Aoki S, Hayakawa M, Ozaki H, et al. ST2 gene expression is proliferation-dependent and its ligand, IL-33, induces inflammatory reaction in endothelial cells. Mol Cell Biochem. 2010;335(1–2):75–81.
   PubMed Web of Science ®Google Scholar
• Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov. 2008;7(10):827–840.
   PubMed Web of Science ®Google Scholar
• Brunner M, Krenn C, Roth G, et al. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med. 2004;30(7):1468–1473.
   PubMed Web of Science ®Google Scholar
• Hoogerwerf JJ, Tanck MWT, van Zoelen MAD, et al. Soluble ST2 plasma concentrations predict mortality in severe sepsis. Intensive Care Med. 2010;36(4):630–637.
   PubMed Web of Science ®Google Scholar
• Miller AM, Xu D, Asquith DL, et al. IL-33 reduces the development of atherosclerosis. J Exp Med. 2008;205(2):339–346.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Morrow DA, Higgins LJ, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008;117(15):1936–1944.
   PubMed Web of Science ®Google Scholar
• Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106(23):2961–2966.
   PubMed Web of Science ®Google Scholar
• Granne I, Southcombe JH, Snider JV, et al. ST2 and IL-33 in pregnancy and pre-eclampsia. PLOS One. 2011;6(9):e24463.
   PubMed Web of Science ®Google Scholar
• Salker MS, Nautiyal J, Steel JH, et al. Disordered IL-33/ST2 activation in decidualizing stromal cells prolongs uterine receptivity in women with recurrent pregnancy loss. PLOS One. 2012;7(12):e52252.
   PubMed Web of Science ®Google Scholar
• Kaitu’u-Lino Tu J, Tuohey L, Tong S. Maternal serum interleukin-33 and soluble ST2 across early pregnancy, and their association with miscarriage. J Reprod Immunol. 2012;95(1–2):46–49.
   PubMed Web of Science ®Google Scholar
• Stampalija T, Chaiworapongsa T, Romero R, et al. Soluble ST2, a modulator of the inflammatory response, in preterm and term labor. J Matern Fetal Neonat. 2014;27(2):111–121.
   PubMed Web of Science ®Google Scholar
• Stampalija T, Romero R, Korzeniewski SJ, et al. Soluble ST2 in the fetal inflammatory response syndrome: in vivo evidence of activation of the anti-inflammatory limb of the immune response. J Matern Fetal Neonat. 2013;26(14):1384–1393.
   PubMed Web of Science ®Google Scholar
• Romero R, Chaemsaithong P, Tarca AL, et al. Maternal plasma-soluble ST2 concentrations are elevated prior to the development of early and late onset preeclampsia – a longitudinal study. J Matern Fetal Neonat. 2018;31(4):418–432.
   PubMed Web of Science ®Google Scholar
• Stampalija T, Chaiworapongsa T, Romero R, et al. Maternal plasma concentrations of sST2 and angiogenic/anti-angiogenic factors in preeclampsia. J Matern Fetal Neonat. 2013;26(14):1359–1370.
   PubMed Web of Science ®Google Scholar
• Docheva N, Romero R, Chaemsaithong P, et al. The profiles of soluble adhesion molecules in the "great obstetrical syndromes". J Matern Fetal Neonat. 2019;32(13):2113–2136.
   PubMed Web of Science ®Google Scholar
• Lees CC, Romero R, Stampalija T, et al. Clinical opinion: the diagnosis and management of suspected fetal growth restriction: an evidence-based approach. Am J Obstet Gynecol. 2022;226(3):366–378.
   PubMed Web of Science ®Google Scholar
• Lees CC, Stampalija T, Baschat A, et al. ISUOG practice guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction. Ultrasound Obstet Gynecol. 2020;56(2):298–312.
   PubMed Web of Science ®Google Scholar
• Deter RL, Lee W, Yeo L, et al. Individualized growth assessment: conceptual framework and practical implementation for the evaluation of fetal growth and neonatal growth outcome. Am J Obstet Gynecol. 2018;218(2):S656–S678.
   PubMed Web of Science ®Google Scholar
• Voigt HJ, Becker V. Doppler flow measurements and histomorphology of the placental bed in uteroplacental insufficiency. J Perinat Med. 1992;20(2):139–147.
   PubMed Web of Science ®Google Scholar
• Lin S, Shimizu I, Suehara N, et al. Uterine artery Doppler velocimetry in relation to trophoblast migration into the myometrium of the placental bed. Obstet Gynecol. 1995;85(5 Pt 1):760–765.
   PubMed Web of Science ®Google Scholar
• Olofsson P, Laurini RN, Marsál K. A high uterine artery pulsatility index reflects a defective development of placental bed spiral arteries in pregnancies complicated by hypertension and fetal growth retardation. Eur J Obstet Gynecol Reprod Biol. 1993;49(3):161–168.
   PubMed Web of Science ®Google Scholar
• Sibai BM, Ewell M, Levine RJ, et al. Risk factors associated with preeclampsia in healthy nulliparous women. The Calcium for Preeclampsia Prevention (CPEP) Study Group. Am J Obstet Gynecol. 1997;177:1003–1010.
   Google Scholar
• Alexander GR, Himes JH, Kaufman RB, et al. A United States national reference for fetal growth. Obstet Gynecol. 1996;87(2):163–168.
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Kusanovic JP, et al. Plasma soluble endoglin concentration in pre-eclampsia is associated with an increased impedance to flow in the maternal and fetal circulations. Ultrasound Obstet Gynecol. 2010;35(2):155–162.
   PubMed Web of Science ®Google Scholar
• Kurmanavicius J, Florio I, Wisser J, et al. Reference resistance indices of the umbilical, fetal middle cerebral and uterine arteries at 24–42 weeks of gestation. Ultrasound Obstet Gynecol. 1997;10(2):112–120.
   PubMed Web of Science ®Google Scholar
• Arduini D, Rizzo G. Normal values of pulsatility index from fetal vessels: a cross-sectional study on 1556 healthy fetuses. J Perinat Med. 1990;18(3):165–172.
   PubMed Web of Science ®Google Scholar
• Trudinger BJ, Cook CM, Giles WB, et al. Fetal umbilical artery velocity waveforms and subsequent neonatal outcome. Br J Obstet Gynaecol. 1991;98(4):378–384.
   PubMedGoogle Scholar
• Meisel C, Bonhagen K, Löhning M, et al. Regulation and function of T1/ST2 expression on CD4+ T cells: induction of type 2 cytokine production by T1/ST2 cross-linking. J Immunol. 2001;166(5):3143–3150.
   PubMed Web of Science ®Google Scholar
• Griesenauer B, Paczesny S. The ST2/IL-33 axis in immune cells during inflammatory diseases. Front Immunol. 2017;8:475.
   PubMed Web of Science ®Google Scholar
• Gächter T, Werenskiold AK, Klemenz R. Transcription of the interleukin-1 receptor-related T1 gene is initiated at different promoters in mast cells and fibroblasts. J Biol Chem. 1996;271(1):124–129.
   PubMed Web of Science ®Google Scholar
• Bergers G, Reikerstorfer A, Braselmann S, et al. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J. 1994;13(5):1176–1188.
   PubMed Web of Science ®Google Scholar
• Löhning M, Stroehmann A, Coyle AJ, et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci U S A. 1998;95(12):6930–6935.
   PubMed Web of Science ®Google Scholar
• Trajkovic V, Sweet MJ, Xu D. T1/ST2 – an IL-1 receptor-like modulator of immune responses. Cytokine Growth Factor Rev. 2004;15(2–3):87–95.
   PubMed Web of Science ®Google Scholar
• Yanagisawa K, Naito Y, Kuroiwa K, et al. The expression of ST2 gene in helper T cells and the binding of ST2 protein to myeloma-derived RPMI8226 cells. J Biochem. 1997;121(1):95–103.
   PubMed Web of Science ®Google Scholar
• Mildner M, Storka A, Lichtenauer M, et al. Primary sources and immunological prerequisites for sST2 secretion in humans. Cardiovasc Res. 2010;87(4):769–777.
   PubMed Web of Science ®Google Scholar
• Chen WY, Li LC, Yang JL. Emerging roles of IL-33/ST2 axis in renal diseases. Int J Mol Sci. 2017;18:783.
   PubMed Web of Science ®Google Scholar
• Tago K, Noda T, Hayakawa M, et al. Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. Biochem Biophys Res Commun. 2001;285(5):1377–1383.
   PubMed Web of Science ®Google Scholar
• Begum S, Perlman BE, Valero-Pacheco N, et al. Dynamic expression of interleukin-33 and ST2 in the mouse reproductive tract is influenced by superovulation. J Histochem Cytochem. 2020;68(4):253–267.
   PubMed Web of Science ®Google Scholar
• Hu W-T, Li M-Q, Liu W, et al. IL-33 enhances proliferation and invasiveness of decidual stromal cells by up-regulation of CCL2/CCR2 via NF-κB and ERK1/2 signaling. Mol Hum Reprod. 2014;20(4):358–372.
   PubMed Web of Science ®Google Scholar
• Fock V, Mairhofer M, Otti GR, et al. Macrophage-derived IL-33 is a critical factor for placental growth. J Immunol. 2013;191(7):3734–3743.
   PubMed Web of Science ®Google Scholar
• Kong W, Gong Y, Zhou R, et al. Soluble ST2, a preeclampsia-related cytokine receptor, is transported bi-directionally across the placenta. Placenta. 2018;63:21–25.
   PubMed Web of Science ®Google Scholar
• Becerra A, Warke RV, de Bosch N, et al. Elevated levels of soluble ST2 protein in dengue virus infected patients. Cytokine. 2008;41(2):114–120.
   PubMed Web of Science ®Google Scholar
• Houghton-Triviño N, Salgado DM, Rodríguez JA, et al. Levels of soluble ST2 in serum associated with severity of dengue due to tumour necrosis factor alpha stimulation. J Gen Virol. 2010;91(Pt 3):697–706.
   PubMedGoogle Scholar
• Guerrero CD, Arrieta AF, Ramirez ND, et al. High plasma levels of soluble ST2 but not its ligand IL-33 is associated with severe forms of pediatric dengue. Cytokine. 2013;61(3):766–771.
   PubMed Web of Science ®Google Scholar
• Shimpo M, Morrow DA, Weinberg EO, et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004;109(18):2186–2190.
   PubMed Web of Science ®Google Scholar
• Sanada S, Hakuno D, Higgins LJ, et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117(6):1538–1549.
   PubMed Web of Science ®Google Scholar
• Shah RV, Januzzi JL. ST2: a novel remodeling biomarker in acute and chronic heart failure. Curr Heart Fail Rep. 2010;7(1):9–14.
   PubMedGoogle Scholar
• Weinberg EO, Shimpo M, Hurwitz S, et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation. 2003;107(5):721–726.
   PubMed Web of Science ®Google Scholar
• Sacks G, Sargent I, Redman C. An innate view of human pregnancy. Immunol Today. 1999;20(3):114–118.
   PubMedGoogle Scholar
• Richani K, Soto E, Romero R, et al. Normal pregnancy is characterized by systemic activation of the complement system. J Matern Fetal Neonatal Med. 2005;17(4):239–245.
   PubMed Web of Science ®Google Scholar
• Naccasha N, Gervasi MT, Chaiworapongsa T, et al. Phenotypic and metabolic characteristics of monocytes and granulocytes in normal pregnancy and maternal infection. Am J Obstet Gynecol. 2001;185(5):1118–1123.
   PubMed Web of Science ®Google Scholar
• Zhao L, Fu J, Ding F, et al. IL-33 and soluble ST2 are associated with recurrent spontaneous abortion in early pregnancy. Front Physiol. 2021;12:789829.
   PubMed Web of Science ®Google Scholar
• Fan W, Kang W, Li T, et al. Interleukin-33 and its receptor soluble suppression of tumorigenicity 2 in the diagnosis of gestational diabetes mellitus. Int J Clin Pract. 2021;75(12):e14944.
   PubMed Web of Science ®Google Scholar
• Ferrazzi E, Bulfamante G, Mezzopane R, et al. Uterine Doppler velocimetry and placental hypoxic-ischemic lesion in pregnancies with fetal intrauterine growth restriction. Placenta. 1999;20(5–6):389–394.
   PubMed Web of Science ®Google Scholar
• Mugerli S, Ambrožič J, Geršak K, et al. Elevated soluble-St2 concentrations in preeclampsia correlate with echocardiographic parameters of diastolic dysfunction and return to normal values one year after delivery. J Matern Fetal Neonatal Med. 2021;34(3):379–385.
   PubMed Web of Science ®Google Scholar
• Sasmaya PH, Khalid AF, Anggraeni D, et al. Differences in maternal soluble ST2 levels in the third trimester of normal pregnancy versus preeclampsia. Eur J Obstet Gynecol Reprod Biol X. 2022;13:100140.
   PubMedGoogle Scholar
• Southcombe JH, Benton SJ, Hu Y, et al. Measurement of sST2 is comparable to PlGF in the diagnosis of early-onset pre-eclampsia. Pregnancy Hypertens. 2013;3(2):115–117.
   PubMed Web of Science ®Google Scholar
• Bretelle F, Sabatier F, Blann A, et al. Maternal endothelial soluble cell adhesion molecules with isolated small for gestational age fetuses: comparison with pre-eclampsia. BJOG. 2001;108(12):1277–1282.
   PubMed Web of Science ®Google Scholar
• Soto E, Romero R, Richani K, et al. Preeclampsia and pregnancies with small-for-gestational age neonates have different profiles of complement split products. J Matern Fetal Neonatal Med. 2010;23(7):646–657.
   PubMed Web of Science ®Google Scholar
• Chaiworapongsa T, Romero R, Whitten AE, et al. The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia. J Matern Fetal Neonatal Med. 2016;29(8):1214–1228.
   PubMed Web of Science ®Google Scholar
• Erez O, Romero R, Vaisbuch E, et al. Tissue factor activity in women with preeclampsia or SGA: a potential explanation for the excessive thrombin generation in these syndromes. J Matern Fetal Neonatal Med. 2018;31(12):1568–1577.
   PubMed Web of Science ®Google Scholar
• Sekizawa A, Jimbo M, Saito H, et al. Cell-free fetal DNA in the plasma of pregnant women with severe fetal growth restriction. Am J Obstet Gynecol. 2003;188(2):480–484.
   PubMed Web of Science ®Google Scholar